Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 56Sarcoma 2Gynecologic 2Genitourinary 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Dermatologic 1CNS 1Breast 1

Conditions

Urinary Bladder Neoplasms 20Carcinoma, Renal Cell 12Colorectal Neoplasms 10Kidney Neoplasms 8Ovarian Neoplasms 6Neoplasms 5Carcinoma, Transitional Cell 5Urethral Neoplasms 4Stomach Neoplasms 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Colonic Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Urothelial Carcinoma of the Bladder 1

Interventions

pembrolizumab 23Nivolumab 19atezolizumab 9Specimen Handling 8Ipilimumab 8Cyclophosphamide 8Magnetic Resonance Spectroscopy 6fludarabine 5cabozantinib 5Sorafenib 5sargramostim 4Trastuzumab 4Sunitinib 4Bevacizumab 4lenvatinib 3durvalumab 3avelumab 3X-Rays 3Paclitaxel 3Fluorodeoxyglucose F18 3Docetaxel 3Albumin-Bound Paclitaxel 3ulixertinib 2spartalizumab 2relatlimab 2regorafenib 2palbociclib 2epacadostat 2enzalutamide 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Fluorouracil × Genitourinary × Clear all
NCT05919264 2026-05-12

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Parabilis Medicines, Inc.

Phase 1/2 Recruiting
595 enrolled
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡